Results 91 to 100 of about 180,701 (284)
PLoS ONE, 2021 BackgroundBackground Population-based data on SARS-CoV-2 infection in pregnancy and assessment of passive immunity to the neonate, is lacking. We profiled the maternal and fetal response using a combination of viral RNA from naso-pharyngeal swabs and ...
Kate Glennon +24 more
doaj +1 more source
Heliyon, 2023 The human infectious disease COVID-19 caused by the SARS-CoV-2 virus has become a major threat to global public health. Developing a vaccine is the preferred prophylactic response to epidemics and pandemics.
Nancy E. Hernandez +10 more
doaj +1 more source
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Stem Cell Research, 2021 SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers of infected patients and death toll keep vigorous increasing, curbing the progression of the pandemic is an urgent goal.
Xiaojie, Shi +4 more
openaire +3 more sources
Microphysiological Systems of Lymphatics and Immune Organs
Advanced Healthcare Materials, EarlyView.This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain +2 more
wiley +1 more source
Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]
, 2011 Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet +10 more
core +1 more source
Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization
Advanced Healthcare Materials, EarlyView.A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng
Molood Behbahanipour +11 more
wiley +1 more source
Scientific Reports, 2021 Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19 disease. Therapeutic antibodies are being developed that interact with the viral spike proteins to limit viral infection of epithelium. We have applied a method
Adam Leach +7 more
doaj +1 more source
A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes [PDF]
, 2012 Copyright @ 2012, American Society for Microbiology.Human coronaviruses are associated with upper respiratory tract infections that occasionally spread to the lungs and other organs.
A. Vabret +61 more
core +3 more sources
Investigating the Dark Figure of COVID-19 Cases in Austria: Borrowing From the Decode Genetics Study in Iceland [PDF]
, 2020 The number of undetected cases of SARS-CoV-2 infections is expected to be a multiple of the reported figures mainly due to the assumed high proportion of asymptomatic infections and to limited availability of trustworthy testing resources. Relying on the
Hirk, Rainer +2 more
core +1 more source
Advanced Healthcare Materials, EarlyView.We present a strategy to enhance magnetic hyperthermia therapy by modulating nanoparticle–cell interactions. Antibody‐functionalized magnetic nanoparticles targeting the low‐internalizing CCR9 receptor enable spatially controlled membrane anchoring, reducing aggregation and maximizing heat generation under alternating magnetic fields.
David Egea‐Benavente +5 more
wiley +1 more source